viloxazine
Sign in to saveAlso known as 2-((2-Ethoxyphenoxy)methyl)morpholine, Viloxazina, Viloxazinum, Qelbree
Viloxazine, sold under the brand name Qelbree among others, is a selective norepinephrine reuptake inhibitor medication that is indicated in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken orally. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form, although current evidence indicates that it is significantly les
Key facts
- Drug.UNII2
- OQW30I1332
- Drug.KEGG
- D08673
- Drug.KEGG2
- D02572
- Drug.ChEBI
- 94405
- Drug.ChEMBL
- 306700
- Drug.ChEMBL2
- 2106483
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 470630208
- Drug.image
- Viloxazine structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 175
- Drug.image2
- Viloxazine_3D-Skeletal_Formula.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 175
- Drug.chirality
- Racemic mixture
- Drug.tradename
- Qelbree, others
- Drug.DailyMedID
- Viloxazine
via Wikipedia infobox
Research
442 papers- Viloxazine.2012
- Viloxazine.2006
- Viloxazine: Pediatric First Approval.Paediatric drugs · 2021
- Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults.CNS drugs · 2025
- Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder.Frontiers in psychiatry · 2021
via PubMed
Wikidata facts
- Mass
- 237.136493
Show 4 more facts
- chemical formula
- C₁₃H₁₉NO₃
- Commons category
- Viloxazine
- canonical SMILES
- CCOC1=CC=CC=C1OCC2CNCCO2
- defined daily dose
- 0.2
Sources (3)
via Wikidata · CC0
~11 min read
Article
21 sectionsContents
- Medical uses
- Attention deficit hyperactivity disorder
- Depression
- Available forms
- Side effects
- Interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Absorption
- Distribution
- Metabolism
- Elimination
- Chemistry
- Analogues
- History
- Society and culture
- Brand names
- Research
- References
- External links
Viloxazine, sold under the brand name Qelbree among others, is a selective norepinephrine reuptake inhibitor medication that is indicated in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken orally. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form, although current evidence indicates that it is significantly less effective at reducing ADHD symptoms compared to stimulant medications like methylphenidate.
Side effects of viloxazine include insomnia, headache, somnolence, fatigue, nausea, vomiting, decreased appetite, dry mouth, constipation, irritability, increased heart rate, and increased blood pressure. Rarely, the medication may cause suicidal thoughts and behaviors. It can also activate mania or hypomania in people with bipolar disorder. Viloxazine acts as a selective norepinephrine reuptake inhibitor (sNRI). The immediate-release form has an elimination half-life of 2.5hours while the half-life of the extended-release form is 7hours.